Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 0.03 mg; drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: lactose monohydrate; purified talc; titanium dioxide; magnesium stearate; hypromellose; microcrystalline cellulose - indications: yasmin is indicated for use as an oral contraceptive.

United States - English - NLM (National Library of Medicine)

central texas community health centers - drospirenone (unii: n295j34a25) (drospirenone - unii:n295j34a25), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - drospirenone 3 mg - yasmin® is indicated for use by women to prevent pregnancy. do not prescribe yasmin to women who are known to have the following: there is little or no increased risk of birth defects in women who inadvertently use cocs during early pregnancy. epidemiologic studies and meta-analyses have not found an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to low dose cocs prior to conception or during early pregnancy. the administration of cocs to induce withdrawal bleeding should not be used as a test for pregnancy. cocs should not be used during pregnancy to treat threatened or habitual abortion. women who do not breastfeed may start cocs no earlier than four weeks postpartum. when possible, advise the nursing mother to use other forms of contraception until she has weaned her child. estrogen-containing cocs can reduce milk production in breastfeeding mothers. this is less likely to occur once breastfeeding is well-established; howe

United States - English - NLM (National Library of Medicine)

bayer healthcare pharmaceuticals inc. - drospirenone (unii: n295j34a25) (drospirenone - unii:n295j34a25), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - drospirenone 3 mg - yasmin® is indicated for use by females of reproductive potential to prevent pregnancy. yasmin is contraindicated in females who are known to have or develop the following conditions: there is no use for contraception in pregnancy; therefore, yasmin should be discontinued during pregnancy. epidemiologic studies and meta-analyses have not found an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to chcs before conception or during early pregnancy. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4 percent and 15 to 20 percent, respectively. a retrospective database study of women in norway, that included 44,734 pregnancies of which 368 were women who inadvertently took drospirenone/ethinyl estradiol during the first trimester of a pregnancy, found there were no adverse effects on pre-term birth, small for gestational age, or birth w

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - drospirenone (unii: n295j34a25) (drospirenone - unii:n295j34a25), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - drospirenone 3 mg - yasmin is indicated for use by women to prevent pregnancy. do not prescribe yasmin to women who are known to have the following: - renal impairment - adrenal insufficiency - a high risk of arterial or venous thrombotic diseases. examples include women who are known to: smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)] have deep vein thrombosis or pulmonary embolism, now or in the past [see warnings and precautions (5.1)] - smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)] - have deep vein thrombosis or pulmonary embolism, now or in the past [see warnings and precautions (5.1)] - have cerebrovascular disease [see warnings and precautions (5.1)] - have coronary artery disease [see warnings and precautions (5.1)] - have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings and precautions (5.1)] - have inherited or acquired hypercoagulopa

Israel - English - Ministry of Health

bayer israel ltd - drospirenone; ethinylestradiol as betadex clathrate; levomefolate calcium; levomefolate calcium - film coated tablets - levomefolate calcium 0.451 mg; ethinylestradiol as betadex clathrate 0.03 mg; drospirenone 3 mg; levomefolate calcium 0.451 mg - estradiol, combinations - oral contraceptive. in women who choose to use an oral contraceptive as their method of contraception, to raise folate levels for the purpose of reducing the risk of a neural tube defect in a pregnancy conceived while taking the product or shortly after discontinuing the product.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - drospirenone 3mg; ethinylestradiol 30ug - tablet - active: drospirenone 3mg ethinylestradiol 30ug excipient: hypromellose iron oxide yellow lactose monohydrate macrogol 6000 magnesium stearate maize starch povidone purified talc starch titanium dioxide hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose purified talc titanium dioxide hypromellose lactose monohydrate magnesium stearate maize starch povidone purified talc titanium dioxide - oral contraception

Singapore - English - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - drospirenone; ethinylestradiol - tablet, film coated - 3 mg - drospirenone 3 mg; ethinylestradiol 0.03 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - drospirenone; ethinyloestradiol -

Israel - English - Ministry of Health

bayer israel ltd - drospirenone; ethinylestradiol - film coated tablets - drospirenone 3 mg; ethinylestradiol 0.03 mg - drospirenone and estrogen - drospirenone and estrogen - oral contraception.

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

bayer (pty) ltd û isando - tablet - see ingredients - each tablet contains drospirenone 3,0 mg ethinylestradiol 0,03 mg levomefolate calcium 0,451 mg